Use of Acid Sphingomyelinase for Cancer Therapy

Advances in Cancer Research

Volumn 117, Issue , 2013, Pages 91-115

  Savić, Radoslav ^a   Schuchman, Edward H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adjunct; Cancer; Combination; Drug; Enzyme; Lipid; Sphingomyelinase; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDASE; CERAMIDE; RECOMBINANT SPHINGOMYELIN PHOSPHODIESTERASE; SORAFENIB; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENICITY; CELL DEATH; CELL MEMBRANE; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REPLACEMENT; GENE OVEREXPRESSION; HUMAN; KNOCKOUT MOUSE; LIPID METABOLISM; LIVER CELL CARCINOMA; MELANOMA; METASTASIS; NIEMANN PICK DISEASE; NONHUMAN; PH; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 84871817869     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394274-6.00004-2     Document Type: Chapter

References (131)

1. Akgul C., Moulding D.A., Edwards S.W. Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications. Cellular and Molecular Life Sciences 2004, 61:2189-2199.
2. Andrieu-Abadie N., Gouaze V., Salvayre R., Levade T. Ceramide in apoptosis signaling: Relationship with oxidative stress. Free Radical Biology & Medicine 2001, 31:717-728.
3. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Current Topics in Medicinal Chemistry 2001, 1:277-351.
4. Bernardo K., Krut O., Wiegmann K., Kreder D., Micheli M., Schafer R., et al. Purification and characterization of a magnesium-dependent neutral sphingomyelinase from bovine brain. The Journal of Biological Chemistry 2000, 275:7641-7647.
5. Bertolaso L., Gibellini D., Secchiero P., Previati M., Falgione D., Visani G., et al. Accumulation of catalytically active PKC-zeta into the nucleus of HL-60 cell line plays a key role in the induction of granulocytic differentiation mediated by all-trans retinoic acid. British Journal of Haematology 1998, 100:541-549.
6. Bezombes C., Grazide S., Garret C., Fabre C., Quillet-Mary A., Muller S., et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004, 104:1166-1173.
7. Biswal S.S., Datta K., Acquaah-Mensah G.K., Kehrer J.P. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology 2000, 154:45-53.
8. Brady R.O., Kanfer J.N., Mock M.B., Fredrickson D.S. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proceedings of the National Academy of Sciences of the United States of America 1966, 55:366-369.
9. Bretscher M.S. Membrane structure: Some general principles. Science 1973, 181:622-629.
10. Caldwell S.H., Crespo D.M., Kang H.S., Al-Osaimi A.M. Obesity and hepatocellular carcinoma. Gastroenterology 2004, 127:S97-S103.
11. Cao Y., Arbiser J., D'Amato R.J., D'Amore P.A., Ingber D.E., Kerbel R., et al. Forty-year journey of angiogenesis translational research. Science Translational Medicine 2011, 3:114rv3.
12. Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D., Cummings C., et al. Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis. Science 1997, 277:228-231.
13. Chalfant C.E., Ogretmen B., Galadari S., Kroesen B.J., Pettus B.J., Hannun Y.A. FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1. The Journal of Biological Chemistry 2001, 276:44848-44855.
14. Chalfant C.E., Szulc Z., Roddy P., Bielawska A., Hannun Y.A. The structural requirements for ceramide activation of serine-threonine protein phosphatases. Journal of Lipid Research 2004, 45:496-506.
15. Crawford K.W., Bittman R., Chun J., Byun H.S., Bowen W.D. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cellular and Molecular Biology (Noisy-le-Grand, France) 2003, 49:1017-1023.
16. Crocker A.C. The cerebral defect in Tay-Sachs disease and Niemann-Pick disease. Journal of Neurochemistry 1961, 7:69-80.
17. Crocker A.C., Farber S. Niemann-Pick disease: A review of eighteen patients. Medicine (Baltimore) 1958, 37:1-95.
18. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381:800-803.
19. Date T., Mitsutake S., Igarashi Y. Ceramide kinase expression is altered during macrophage-like cell differentiation of the leukemia cell line HL-60. In Vitro Cellular and Developmental Biology. Animal 2007, 43:321-323.
20. da Veiga Pereira L., Desnick R.J., Adler D.A., Disteche C.M., Schuchman E.H. Regional assignment of the human acid sphingomyelinase gene (SMPD1) by PCR analysis of somatic cell hybrids and in situ hybridization to 11p15.1-p15.4. Genomics 1991, 9:229-234.
21. Devalapally H., Duan Z., Seiden M.V., Amiji M.M. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clinical Cancer Research 2008, 14:3193-3203.
22. Draper J.M., Xia Z., Smith R.A., Zhuang Y., Wang W., Smith C.D. Discovery and evaluation of inhibitors of human ceramidase. Molecular Cancer Therapeutics 2011, 10:2052-2061.
23. Duan R.D., Hertervig E., Nyberg L., Hauge T., Sternby B., Lillienau J., et al. Distribution of alkaline sphingomyelinase activity in human beings and animals. Tissue and species differences. Digestive Diseases and Sciences 1996, 41:1801-1806.
24. El-Serag H.B., Davila J.A., Petersen N.J., McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Annals of Internal Medicine 2003, 139:817-823.
25. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
26. EMA. (2001). Orphan designation EU/3/01/056. Nov 12, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000157.jsp&mid=WC0b01ac058001d12b&murl=menus/medicines/medicines.jsp&jsenabled=true.
27. Fadok V.A., Bratton D.L., Frasch S.C., Warner M.L., Henson P.M. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death and Differentiation 1998, 5:551-562.
28. FDA. (2003). List of orphan products designated and approved as of December 31, 2003. Nov 12, 2012. http://www.fda.gov/ohrms/dockets/dailys/04/June04/060304/84n-0102-lst0101-01.pdf.
29. Ferlinz K., Hurwitz R., Moczall H., Lansmann S., Schuchman E.H., Sandhoff K. Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis. European Journal of Biochemistry 1997, 243:511-517.
30. Flowers M., Fabrias G., Delgado A., Casas J., Abad J.L., Cabot M.C. C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Research and Treatment 2012, 133:447-458.
31. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. The Journal of Experimental Medicine 1971, 133:275-288.
32. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
33. Garnacho C., Dhami R., Simone E., Dziubla T., Leferovich J., Schuchman E.H., et al. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. The Journal of Pharmacology and Experimental Therapeutics 2008, 325:400-408.
34. Geley S., Hartmann B.L., Kofler R. Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl-2, but not by CrmA. FEBS Letters 1997, 400:15-18.
35. Goni F.M., Alonso A. Sphingomyelinases: Enzymology and membrane activity. FEBS Letters 2002, 531:38-46.
36. Grassme H., Jekle A., Riehle A., Schwarz H., Berger J., Sandhoff K., et al. CD95 signaling via ceramide-rich membrane rafts. The Journal of Biological Chemistry 2001, 276:20589-20596.
37. Grassme H., Riethmuller J., Gulbins E. Biological aspects of ceramide-enriched membrane domains. Progress in Lipid Research 2007, 46:161-170.
38. Haimovitz-Friedman A., Cordon-Cardo C., Bayoumy S., Garzotto M., McLoughlin M., Gallily R., et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. The Journal of Experimental Medicine 1997, 186:1831-1841.
39. Hakomori S. Glycolipids of tumor cell membrane. Advances in Cancer Research 1973, 18:265-315.
40. Hannun Y.A., Bell R.M. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 1989, 243:500-507.
41. Hannun Y.A., Obeid L.M. Many ceramides. The Journal of Biological Chemistry 2011, 286:27855-27862.
42. He X., Miranda S.R., Xiong X., Dagan A., Gatt S., Schuchman E.H. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochimica et Biophysica Acta 1999, 1432:251-264.
43. Heinrich M., Neumeyer J., Jakob M., Hallas C., Tchikov V., Winoto-Morbach S., et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death and Differentiation 2004, 11:550-563.
44. Hemsley K.M., Hopwood J.J. Emerging therapies for neurodegenerative lysosomal storage disorders-From concept to reality. Journal of Inherited Metabolic Disease 2011, 34:1003-1012.
45. Herr I., Wilhelm D., Bohler T., Angel P., Debatin K.M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. The EMBO Journal 1997, 16:6200-6208.
46. Holopainen J.M., Subramanian M., Kinnunen P.K. Sphingomyelinase induces lipid microdomain formation in a fluid phosphatidylcholine/sphingomyelin membrane. Biochemistry 1998, 37:17562-17570.
47. Horinouchi K., Erlich S., Perl D.P., Ferlinz K., Bisgaier C.L., Sandhoff K., et al. Acid sphingomyelinase deficient mice: A model of types A and B Niemann-Pick disease. Nature Genetics 1995, 10:288-293.
48. Huang C., Ma W., Ding M., Bowden G.T., Dong Z. Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. The Journal of Biological Chemistry 1997, 272:27753-27757.
49. Hurwitz R., Ferlinz K., Vielhaber G., Moczall H., Sandhoff K. Processing of human acid sphingomyelinase in normal and I-cell fibroblasts. The Journal of Biological Chemistry 1994, 269:5440-5445.
50. Huwiler A., Brunner J., Hummel R., Vervoordeldonk M., Stabel S., van den Bosch H., et al. Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:6959-6963.
51. Igney F.H., Krammer P.H. Death and anti-death: Tumour resistance to apoptosis. Nature Reviews. Cancer 2002, 2:277-288.
52. Jacotot E., Costantini P., Laboureau E., Zamzami N., Susin S.A., Kroemer G. Mitochondrial membrane permeabilization during the apoptotic process. Annals of the New York Academy of Sciences 1999, 887:18-30.
53. Kanfer J.N., Young O.M., Shapiro D., Brady R.O. The metabolism of sphingomyelin. I. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue. The Journal of Biological Chemistry 1966, 241:1081-1084.
54. Kashkar H., Wiegmann K., Yazdanpanah B., Haubert D., Kronke M. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. The Journal of Biological Chemistry 2005, 280:20804-20813.
55. Kawase M., Watanabe M., Kondo T., Yabu T., Taguchi Y., Umehara H., et al. Increase of ceramide in adriamycin-induced HL-60 cell apoptosis: Detection by a novel anti-ceramide antibody. Biochimica et Biophysica Acta 2002, 1584:104-114.
56. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 1972, 26:239-257.
57. Kim M.Y., Linardic C., Obeid L., Hannun Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. The Journal of Biological Chemistry 1991, 266:484-489.
58. Klenk E. Uber die Natur der Phosphatide in der Milz in Niemann-Pickscher Krankheit. Zeitschrift fur physikalische Chemie 1934, 229:151-156.
59. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews. Drug Discovery 2004, 3:711-715.
60. Komatsu M., Takahashi T., Abe T., Takahashi I., Ida H., Takada G. Evidence for the association of ultraviolet-C and H(2)O(2)-induced apoptosis with acid sphingomyelinase activation. Biochimica et Biophysica Acta 2001, 1533:47-54.
61. Koval M., Pagano R.E. Intracellular transport and metabolism of sphingomyelin. Biochimica et Biophysica Acta 1991, 1082:113-125.
62. Lachmann R.H. Enzyme replacement therapy for lysosomal storage diseases. Current Opinion in Pediatrics 2011, 23:588-593.
63. Lacour S., Hammann A., Grazide S., Lagadic-Gossmann D., Athias A., Sergent O., et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Research 2004, 64:3593-3598.
64. Lee O.H., Kim Y.M., Lee Y.M., Moon E.J., Lee D.J., Kim J.H., et al. Sphingosine 1-phosphate induces angiogenesis: Its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochemical and Biophysical Research Communications 1999, 264:743-750.
65. Licht T., Tsirulnikov L., Reuveni H., Yarnitzky T., Ben-Sasson S.A. Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 2003, 102:2099-2107.
66. Lin C.F., Chen C.L., Lin Y.S. Ceramide in apoptotic signaling and anticancer therapy. Current Medicinal Chemistry 2006, 13:1609-1616.
67. Litvak D.A., Bilchik A.J., Cabot M.C. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: A novel treatment strategy. Journal of Gastrointestinal Surgery 2003, 7:140-148. discussion 148.
68. Liu X., Elojeimy S., Turner L.S., Mahdy A.E., Zeidan Y.H., Bielawska A., et al. Acid ceramidase inhibition: A novel target for cancer therapy. Frontiers in Bioscience 2008, 13:2293-2298.
69. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. The FASEB Journal 2001, 15:719-730.
70. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. The Lancet 2003, 362:1907-1917.
71. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008, 359:378-390.
72. Lorusso P.M., Eder J.P. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opinion on Investigational Drugs 2008, 17:1013-1028.
73. Macchia M., Barontini S., Bertini S., Di Bussolo V., Fogli S., Giovannetti E., et al. Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. Journal of Medicinal Chemistry 2001, 44:3994-4000.
74. Mathias S., Younes A., Kan C.C., Orlow I., Joseph C., Kolesnick R.N. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science 1993, 259:519-522.
75. McGovern, M. M., Wasserstein, M. P., Kirmse, B., Duvall, L., Schiano, T., Thurberg, B. L., et al. (2009). A phase 1 trial of recombinant human acid sphingomyelinase (rhASM) enzyme replacement therapy in adults with ASM deficiency (ASMD). Nov 12, 2012. http://www.nnpdf.org/documents/niemannpickposterICIEM09FINAL_000.pdf.
76. Megha, London E. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): Implications for lipid raft structure and function. The Journal of Biological Chemistry 2004, 279:9997-10004.
77. Menten M.L., Welton J.P. Lipid analysis in a case of Niemann-Pick disease. American Journal of Diseases of Children (1911) 1946, 72:720-727.
78. Miranda S.R., He X., Simonaro C.M., Gatt S., Dagan A., Desnick R.J., et al. Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. The FASEB Journal 2000, 14:1988-1995.
79. Mitra P., Maceyka M., Payne S.G., Lamour N., Milstien S., Chalfant C.E., et al. Ceramide kinase regulates growth and survival of A549 human lung adenocarcinoma cells. FEBS Letters 2007, 581:735-740.
80. Morales A., Paris R., Villanueva A., Llacuna L., Garcia-Ruiz C., Fernandez-Checa J.C. Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 2007, 26:905-916.
81. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine 1998, 4:1065-1067.
82. Morjani H., Aouali N., Belhoussine R., Veldman R.J., Levade T., Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. International Journal of Cancer 2001, 94:157-165.
83. Muller G., Ayoub M., Storz P., Rennecke J., Fabbro D., Pfizenmaier K. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. The EMBO Journal 1995, 14:1961-1969.
84. Naureckiene S., Sleat D.E., Lackland H., Fensom A., Vanier M.T., Wattiaux R., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000, 290:2298-2301.
85. Nava V.E., Hobson J.P., Murthy S., Milstien S., Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Experimental Cell Research 2002, 281:115-127.
86. NCI. (2011). Developmental therapeutics program-Cell lines in the in vitro screen. Nov 12, 2012. http://dtp.nci.nih.gov/docs/misc/common_files/cell_list.html.
87. Niemann A. Ein unbekanntes Krankheitsbild. Jahrbuch fur Kindertheologie 1914, 79:1-10.
88. Ogretmen B., Hannun Y.A. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resistance Updates 2001, 4:368-377.
89. Ogretmen B., Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Reviews. Cancer 2004, 4:604-616.
90. Ogretmen B., Kraveka J.M., Schady D., Usta J., Hannun Y.A., Obeid L.M. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. The Journal of Biological Chemistry 2001, 276:32506-32514.
91. Otterbach B., Stoffel W. Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 1995, 81:1053-1061.
92. Park J.H., Schuchman E.H. Acid ceramidase and human disease. Biochimica et Biophysica Acta 2006, 1758:2133-2138.
93. Pick L. über die lipoidzellige Splenohepatomegalie Typus Niemann-Pick als Stoffwechselerkrankung. Medizinische Klinik 1927, 23:1483-1488.
94. Proksch D., Klein J.J., Arenz C. Potent inhibition of acid ceramidase by novel B-13 analogues. Journal of Lipids 2011, 2011:971618.
95. PubChem. (2012). Chemical and physical properties of N-(octadecanoyl)-sphing-4-enine. http://pubchem.ncbi.nlm.nih.gov/summary/summarycgi?cid=5283565.
96. Pyne N.J., Pyne S. Sphingosine 1-phosphate and cancer. Nature Reviews. Cancer 2010, 10:489-503.
97. Richmond A., Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Disease Models & Mechanisms 2008, 1:78-82.
98. Ruckhaberle E., Karn T., Hanker L., Gatje R., Metzler D., Holtrich U., et al. Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. Journal of Cancer Research and Clinical Oncology 2009, 135:81-90.
99. Ruvolo P.P., Deng X., Ito T., Carr B.K., May W.S. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. The Journal of Biological Chemistry 1999, 274:20296-20300.
100. Santana P., Pena L.A., Haimovitz-Friedman A., Martin S., Green D., McLoughlin M., et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996, 86:189-199.
101. Savic R., Azzam T., Eisenberg A., Nedev H., Rosenberg L., Maysinger D. Block-copolymer micelles as carriers of cell signaling modulators for the inhibition of JNK in human islets of Langerhans. Biomaterials 2009, 30:3597-3604.
102. Savic R., Eisenberg A., Maysinger D. Block copolymer micelles as delivery vehicles of hydrophobic drugs: Micelle-cell interactions. Journal of Drug Targeting 2006, 14:343-355.
103. Schadt E.E. Molecular networks as sensors and drivers of common human diseases. Nature 2009, 461:218-223.
104. Schissel S.L., Jiang X., Tweedie-Hardman J., Jeong T., Camejo E.H., Najib J., et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. The Journal of Biological Chemistry 1998, 273:2738-2746.
105. Schissel S.L., Keesler G.A., Schuchman E.H., Williams K.J., Tabas I. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. The Journal of Biological Chemistry 1998, 273:18250-18259.
106. Schissel S.L., Schuchman E.H., Williams K.J., Tabas I. Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. The Journal of Biological Chemistry 1996, 271:18431-18436.
107. Schneider P.B., Kennedy E.P. Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. Journal of Lipid Research 1967, 8:202-209.
108. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nature Reviews. Cancer 2012, 12:39-50.
109. Schuchman E.H. Acid sphingomyelinase, cell membranes and human disease: Lessons from Niemann-Pick disease. FEBS Letters 2010, 584:1895-1900.
110. Schuchman E.H., Levran O., Pereira L.V., Desnick R.J. Structural organization and complete nucleotide sequence of the gene encoding human acid sphingomyelinase (SMPD1). Genomics 1992, 12:197-205.
111. Schuchman E.H., Suchi M., Takahashi T., Sandhoff K., Desnick R.J. Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. The Journal of Biological Chemistry 1991, 266:8531-8539.
112. Seelan R.S., Qian C., Yokomizo A., Bostwick D.G., Smith D.I., Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes, Chromosomes & Cancer 2000, 29:137-146.
113. Sethi N., Kang Y. Unravelling the complexity of metastasis-Molecular understanding and targeted therapies. Nature Reviews. Cancer 2011, 11:735-748.
114. Sietsma H., Veldman R.J., Kok J.W. The involvement of sphingolipids in multidrug resistance. The Journal of Membrane Biology 2001, 181:153-162.
115. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
116. Siskind L.J. Mitochondrial ceramide and the induction of apoptosis. Journal of Bioenergetics and Biomembranes 2005, 37:143-153.
117. Slotte J.P., Hedstrom G., Rannstrom S., Ekman S. Effects of sphingomyelin degradation on cell cholesterol oxidizability and steady-state distribution between the cell surface and the cell interior. Biochimica et Biophysica Acta 1989, 985:90-96.
118. Smith E.L., Schuchman E.H. Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo. Molecular Therapy 2008, 16:1565-1571.
119. Smith E.L., Schuchman E.H. Acid sphingomyelinase enhances the anti-neoplastic effects of irradiation in vitro and in vivo. Mount Sinai Graduate School of Biological Sciences, Vol. Ph.D 2008, Mount Sinai School of Medicine of NYU, New York.
120. Spence M.W., Byers D.M., Palmer F.B., Cook H.W. A new Zn2+-stimulated sphingomyelinase in fetal bovine serum. The Journal of Biological Chemistry 1989, 264:5358-5363.
121. Sugiura M., Kono K., Liu H., Shimizugawa T., Minekura H., Spiegel S., et al. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. The Journal of Biological Chemistry 2002, 277:23294-23300.
122. Tagaram H.R., Divittore N.A., Barth B.M., Kaiser J.M., Avella D., Kimchi E.T., et al. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 2011, 60:695-701.
123. Valcarcel J., Green M.R. The SR protein family: Pleiotropic functions in pre-mRNA splicing. Trends in Biochemical Sciences 1996, 21:296-301.
124. Wan Q., Schuchman E.H. A novel polymorphism in the human acid sphingomyelinase gene due to size variation of the signal peptide region. Biochimica et Biophysica Acta 1995, 1270:207-210.
125. Wenk M.R. The emerging field of lipidomics. Nature Reviews. Drug Discovery 2005, 4:594-610.
126. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
127. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004, 64:7099-7109.
128. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-947.
129. Xu X., Bittman R., Duportail G., Heissler D., Vilcheze C., London E. Effect of the structure of natural sterols and sphingolipids on the formation of ordered sphingolipid/sterol domains (rafts). Comparison of cholesterol to plant, fungal, and disease-associated sterols and comparison of sphingomyelin, cerebrosides, and ceramide. The Journal of Biological Chemistry 2001, 276:33540-33546.
130. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997, 275:1129-1132.
131. Zhang H., Li W., Sun S., Yu S., Zhang M., Zou F. Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase. Cell Proliferation 2012, 45:167-175.